Tackling vancomycin-resistant bacteria with 'lipophilic-vancomycin-carbohydrate conjugates'

Area of Science:

• Microbiology
• Medicinal Chemistry
• Drug Discovery

Background:

• Vancomycin is a critical antibiotic for Gram-positive infections.
• Vancomycin resistance, particularly in Enterococci (VRE), is a major clinical challenge.
• Resistance arises from alterations in bacterial cell wall precursors, reducing vancomycin's binding affinity.

Purpose of the Study:

• To design and synthesize novel vancomycin-sugar analogs.
• To enhance binding affinity to vancomycin-resistant bacterial targets.
• To resensitize vancomycin-resistant bacteria (VRB) to vancomycin treatment.

Main Methods:

• Synthesis of various vancomycin-sugar conjugates.
• Affinity assays to measure binding to altered cell wall precursors (D-Ala-D-Lac).
• Determination of Minimum Inhibitory Concentration (MIC) values against VRE strains.

Main Results:

• An optimized vancomycin-sugar conjugate showed a 150-fold increase in binding affinity.
• This conjugate reduced MIC values against VRE (VanA phenotype) from 750 to 36 μM.
• A lipophilic vancomycin-sugar conjugate demonstrated >1000-fold and 250-fold improved efficacy against VanA and VanB VRE strains, respectively.

Conclusions:

• A simple synthetic strategy yields potent vancomycin analogs against VRB.
• These analogs exhibit significantly improved binding and antibacterial activity.
• This approach holds promise for developing next-generation glycopeptide antibiotics to overcome vancomycin resistance.